DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Information source: Melbourne Health
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Impairment After Cardiac Surgery

Intervention: Frusemide (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: Melbourne Health

Official(s) and/or principal investigator(s):
John F Cade, Principal Investigator, Affiliation: Royal Melbourne Hospital, Intensive Care Unit

Summary

The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

Clinical Details

Official title: Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: The incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery.

Secondary outcome:

1. The maximum change in serum creatinine from baseline value during the first 7 days of hospital stay.

2. Incidence of renal failure requiring any form of renal replacement therapy.

3. Duration of post-operative hospital and ICU stay.

4. The maximum Sequential Organ Failure Assessment (SOFA) score in the first 7 days of hospital stay.

Detailed description: All patients will receive standard supportive care based on current established management practice of cardio-thoracic patients. The only difference in treatment will be the randomisation of patients to receive/not receive protocolised administration of frusemide targeting a urine output. There will be 2 groups of patients. The control group-which will receive frusemide bolus doses if required as determined by the surgeon/consultant physician. The frusemide infusion group-which will be monitored to achieve a trial specified hourly urine output target range of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading dose of frusemide and may also then require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion, from the pre-admission clinics and wards of the Cardiothoracic surgery unit. Potential participants will be identified by the daily review of planned cardiothoracic surgery schedule. Exclusion Criteria: 1. Already in established dialysis dependent chronic renal failure. 2. Known allergy to frusemide 3. Age < 18 years 4. Pregnant

Locations and Contacts

Intensive Care Unit, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
Additional Information


Last updated: April 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017